Ranibizumab

證據等級: L5

預測適應症: 10 個

One-Sentence Summary

Ranibizumab is an anti-VEGF Fab fragment originally developed for neovascular (wet) age-related macular degeneration and diabetic macular edema. The TxGNN model predicts it may also be effective for Severe Nonproliferative Diabetic Retinopathy (NPDR), with 6 clinical trials (including completed Phase 3/4 studies) and 19 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Not on local regulatory record (market status: Not Marketed); internationally approved for neovascular (wet) age-related macular degeneration and diabetic macular edema
Predicted New Indication	Severe Nonproliferative Diabetic Retinopathy
TxGNN Prediction Score	99.99%
Evidence Level	L1
US Market Status	✗ Not Marketed
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap pending DrugBank verification). Based on established pharmacological knowledge, ranibizumab is a recombinant humanized monoclonal antibody Fab fragment that binds and neutralizes vascular endothelial growth factor A (VEGF-A), thereby suppressing pathological retinal neovascularization and vascular permeability.

Severe NPDR and the drug’s established indications (wet AMD, diabetic macular edema) sit on the same disease continuum: VEGF-driven retinal vascular dysfunction. Severe NPDR is the immediate precursor stage to proliferative diabetic retinopathy (PDR) and frequently coexists with diabetic macular edema, the condition ranibizumab is already used to treat. This is not a cross-mechanism extrapolation — it is a direct extension of the drug’s core anti-VEGF activity to an earlier stage of the same underlying vascular pathology.

This mechanistic plausibility is reinforced by late-phase clinical development already underway: a completed Phase 3 trial of the Port Delivery System with ranibizumab specifically in NPDR without macular edema (NCT04503551, completed 2026), and the 2025 Pavilion RCT (PMID 40048178) comparing continuous intraocular ranibizumab release against monitoring alone in NPDR. Taken together, the evidence suggests severe NPDR is a plausible and actively investigated label-extension candidate rather than a speculative model artifact.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02834663	Phase 4	Completed	25	Intravitreal ranibizumab effects on microaneurysm turnover and non-perfused retinal area in NPDR with DME
NCT00444600	Phase 3	Completed	691	Large RCT: ranibizumab ± laser vs triamcinolone ± laser for diabetic macular edema
NCT02634333	Phase 3	Completed	399	Anti-VEGF therapy for prevention of vision-threatening complications in high-risk diabetic retinopathy
NCT03452657	Phase 3	Unknown	118	Intravitreous ranibizumab vs sham for prevention of high-risk DR progression
NCT05222633	N/A	Unknown	1000	Real-world observational study of anti-VEGF therapy across neovascular retinal diseases (includes PDR)
NCT04503551	Phase 3	Completed	174	Port Delivery System with ranibizumab in diabetic retinopathy without center-involved macular edema

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40048178	2025	RCT	JAMA Ophthalmology	Pavilion trial: Port Delivery System with ranibizumab vs monitoring in NPDR without macular edema
39673354	2024	Systematic Review/Meta-analysis	Health Technology Assessment	Anti-VEGF drugs vs laser photocoagulation for diabetic retinopathy
40347224	2025	Systematic Review/Economic Analysis	Health Technology Assessment	Anti-VEGF vs laser photocoagulation for DR, including economic evaluation
36774994	2023	RCT (post-hoc)	Ophthalmology Retina	Baseline DR severity predicts time to DME resolution with ranibizumab in Phase 3 trials
30234859	2018	RCT (DRCR.net Protocol I, 5-yr)	Retina	Changes in diabetic retinopathy severity with ranibizumab treatment for DME
28448655	2017	RCT (secondary analysis)	JAMA Ophthalmology	2-year change in DR severity comparing aflibercept, bevacizumab, and ranibizumab
32606578	2020	RCT (post-hoc, RIDE/RISE)	Clinical Ophthalmology	Predictors of early diabetic retinopathy regression with ranibizumab
35417296	2022	RCT (post-hoc, RIDE/RISE)	Ophthalmic Surgery, Lasers & Imaging Retina	Natural course of DR progression in untreated fellow eyes
36161830	2022	RCT (open-label extension, RIDE/RISE)	BMJ Open Ophthalmology	Effect of less frequent ranibizumab dosing on DR Severity Scale scores
33966556	2021	Review	Expert Opinion on Biological Therapy	Overview of ranibizumab’s role in treating diabetic retinopathy

US Market Information

Currently not marketed in this jurisdiction — no license records are on file (total_licenses = 0).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Severe NPDR represents an L1 evidence-level candidate — supported by multiple completed Phase 3 RCTs and systematic reviews — with a mechanistic link to ranibizumab’s existing anti-VEGF activity so direct it amounts to a natural extension along the diabetic retinopathy severity spectrum rather than a novel mechanistic hypothesis. However, this jurisdiction currently has no marketing authorization, formal MOA documentation, or label safety data on file for this drug.

To proceed, the following is needed:

TFDA/local label warnings and contraindications (currently blocking — DG001)
Formal MOA documentation via DrugBank API (DG002)
Regulatory pathway assessment given the drug is not currently marketed locally
Safety monitoring plan for repeat intravitreal dosing in an NPDR population (endophthalmitis, intraocular pressure, thromboembolic risk)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.